{
    "nctId": "NCT01959386",
    "briefTitle": "A Study of Trastuzumab Subcutaneous in Participants With Human Epidermal Growth Factor Receptor-2 (HER2) Positive Early Breast Cancer",
    "officialTitle": "Clinical Practice Surveillance of the Use of Herceptin\u00ae Subcutaneous in Patients With HER2-Positive Early Breast Cancer (HerSCin)",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1006,
    "primaryOutcomeMeasure": "Percentage of Participants With Pathologic Complete Response (pCR) (For Participants Treated in Neo-Adjuvant Setting), According to Response Evaluation Criteria in Solid Tumor (RECIST), or Modified RECIST, or Cheson Criteria (As per Center Practice)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed adenocarcinoma of the breast\n* HER2-positive tumor\n* Eligible for neo-adjuvant or adjuvant treatment with trastuzumab SC according to the judgement of the physician Note: As of participant recruitment (date of participant informed consent), retrospective documentation is allowed but limited to up to 9 weeks after initial start of therapy with trastuzumab SC\n\nExclusion Criteria:\n\n* Contraindications according to the Summary of Product Characteristics of Herceptin SC\n* Pregnant and breastfeeding women",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}